NASDAQ:FLKS

Flex Pharma (FLKS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.48
$0.50
50-Day Range
$0.57
$14.51
52-Week Range
$0.26
$1.49
Volume
4,025 shs
Average Volume
2.03 million shs
Market Capitalization
$8.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
FLKS stock logo

About Flex Pharma Stock (NASDAQ:FLKS)

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

FLKS Stock News Headlines

Flex Ltd.: Undervalued With Solid Fundamentals
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
ANGLE release Portrait Flex CTC assay
Flex (NASDAQ: FLEX)
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Flex Ltd.
Folk Club with Lynette Fay
Company to add new flex work space to Shelby
Optimal Flex Plays: We are back baby!
Toyota's first EV will start at $42,000
See More Headlines
Receive FLKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flex Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2019
Today
4/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FLKS
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-21,920,000.00
Net Margins
-1,208.42%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$840,000.00
Book Value
$0.51 per share

Miscellaneous

Free Float
N/A
Market Cap
$9.02 million
Optionable
Not Optionable
Beta
1.65
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. William K. McVicar (Age 61)
    Pres, CEO & Director
  • Dr. Roderick MacKinnon (Age 63)
    Co-Founder & Co-Chair of Scientific Advisory Board
  • Mr. John McCabe (Age 49)
    CFO, Treasurer & Sec.
  • Dr. Thomas C. Wessel (Age 63)
    Outside Advisor
  • Dr. Bruce Bean
    Co-Founder, Co-Chair of Scientific Advisory Board & Board Observer

FLKS Stock Analysis - Frequently Asked Questions

How were Flex Pharma's earnings last quarter?

Flex Pharma Inc (NASDAQ:FLKS) released its earnings results on Wednesday, May, 1st. The biotechnology company reported ($0.12) earnings per share for the quarter. The biotechnology company earned $0.11 million during the quarter. Flex Pharma had a negative trailing twelve-month return on equity of 98.04% and a negative net margin of 1,208.42%.

What other stocks do shareholders of Flex Pharma own?
When did Flex Pharma IPO?

Flex Pharma (FLKS) raised $60 million in an initial public offering on Thursday, January 29th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.

This page (NASDAQ:FLKS) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners